IPHA chairs EFPIA Heads of Association meeting

IPHA Chief Executive Oliver O’Connor chaired the recent EFPIA Heads of Association meeting in Vienna, with vice Chair Anders Blanck from Sweden’s LEEM.

The meeting took place in Vienna to support Austrian pharma associations’ work with Austria’s current EU Presidency and to enable associations from smaller central and eastern European countries to attend.

Industry gears up for Brexit

As great uncertainty continues to prevail surrounding the eventual impact of Brexit, the industry is working in the background with relevant public health stakeholders on appropriate preparedness.

Planning on track for Annual Conference as delegates register for ‘lively’ event

Planning is on track for the IPHA Annual Conference and Dinner as delegates register ahead of the November 1 deadline for an event that promises to engage a range of perspectives about the future of Ireland’s bio-economy.

Code eLearning site tops 4000 users

A total of 4,191 individual users have trained on the IPHA Code eLearning site since its inception in February 2016

Pharmacists key to driving a self care strategy

• Pharmacists and pharmaceutical industry partner in major Self Care awareness campaign: ‘Be Well this Winter – Think Pharmacy’, to promote a focused approach to better patient outcomes
• Promoting increased levels of self care in Ireland would lead to a far more effective system of healthcare
• 92% of people like to be involved in decisions about their own health and medication

Industry presses to protect IP Incentives

IPHA is pressing the Irish Government and our MEPs to protect the IP incentives regime which is in danger of erosion by proposed legislation in Brussels.

Sharp Rise in Health Budget But Patients Still Left Waiting For Innovative Medicines - IPHA

As the Government announced the Budget today [Wednesday], the Irish Pharmaceutical Healthcare Association (IPHA) has said it was very disappointing that enough money could not be found in the expanded allocation for health to cover the costs of making new innovative medicines available to patients.